263 related articles for article (PubMed ID: 25875653)
1. An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.
Rausch MP; Hastings KT
PLoS One; 2015; 10(4):e0123332. PubMed ID: 25875653
[TBL] [Abstract][Full Text] [Related]
2. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.
Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT
J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223
[TBL] [Abstract][Full Text] [Related]
3. GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.
Rausch MP; Hastings KT
J Invest Dermatol; 2012 Jan; 132(1):154-62. PubMed ID: 21833020
[TBL] [Abstract][Full Text] [Related]
4. GILT in Thymic Epithelial Cells Facilitates Central CD4 T Cell Tolerance to a Tissue-Restricted, Melanoma-Associated Self-Antigen.
Rausch MP; Meador LR; Metzger TC; Li H; Qiu S; Anderson MS; Hastings KT
J Immunol; 2020 Jun; 204(11):2877-2886. PubMed ID: 32269095
[TBL] [Abstract][Full Text] [Related]
5. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
[TBL] [Abstract][Full Text] [Related]
7. High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.
Brandmaier AG; Leitner WW; Ha SP; Sidney J; Restifo NP; Touloukian CE
J Immunother; 2009 Sep; 32(7):677-88. PubMed ID: 19561540
[TBL] [Abstract][Full Text] [Related]
8. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.
Jensen SM; Twitty CG; Maston LD; Antony PA; Lim M; Hu HM; Petrausch U; Restifo NP; Fox BA
J Immunol; 2012 Jul; 189(2):767-76. PubMed ID: 22723522
[TBL] [Abstract][Full Text] [Related]
9. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.
Singh V; Ji Q; Feigenbaum L; Leighty RM; Hurwitz AA
J Immunother; 2009; 32(2):129-39. PubMed ID: 19238011
[TBL] [Abstract][Full Text] [Related]
10. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity.
Okano F; Merad M; Furumoto K; Engleman EG
J Immunol; 2005 Mar; 174(5):2645-52. PubMed ID: 15728471
[TBL] [Abstract][Full Text] [Related]
11. Control of central and peripheral tolerance to melanocyte differentiation antigens by GILT.
Becker JC; Schrama D
J Invest Dermatol; 2012 Jan; 132(1):15-7. PubMed ID: 22158609
[TBL] [Abstract][Full Text] [Related]
12. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
13. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
14. Aire deficiency promotes TRP-1-specific immune rejection of melanoma.
Zhu ML; Nagavalli A; Su MA
Cancer Res; 2013 Apr; 73(7):2104-16. PubMed ID: 23370329
[TBL] [Abstract][Full Text] [Related]
15. The immune response to melanoma is limited by thymic selection of self-antigens.
Träger U; Sierro S; Djordjevic G; Bouzo B; Khandwala S; Meloni A; Mortensen M; Simon AK
PLoS One; 2012; 7(4):e35005. PubMed ID: 22506061
[TBL] [Abstract][Full Text] [Related]
16. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
Touloukian CE; Leitner WW; Schnur RE; Robbins PF; Li Y; Southwood S; Sette A; Rosenberg SA; Restifo NP
J Immunol; 2003 Feb; 170(3):1579-85. PubMed ID: 12538723
[TBL] [Abstract][Full Text] [Related]
17. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions.
Lambe T; Leung JC; Bouriez-Jones T; Silver K; Makinen K; Crockford TL; Ferry H; Forrester JV; Cornall RJ
J Immunol; 2006 Sep; 177(5):3055-62. PubMed ID: 16920942
[TBL] [Abstract][Full Text] [Related]
18. Immune deviation of 2C transgenic intraepithelial lymphocytes in antigen-bearing hosts.
Guehler SR; Bluestone JA; Barrett TA
J Exp Med; 1996 Aug; 184(2):493-503. PubMed ID: 8760803
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
[TBL] [Abstract][Full Text] [Related]
20. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
Hara I; Takechi Y; Houghton AN
J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
